| 摘要: |
| 芬戈莫德是以真菌的次级代谢产物ISP-Ⅰ为苗头化合物所研发的免疫调节剂,于2010年被FDA批准上市,用以治疗免疫性疾病多发性硬化症。与传统的免疫抑制剂不同,它不影响淋巴细胞的活化和增殖,主要作用于细胞表面的1-磷酸鞘氨醇(S1P)受体来发挥免疫抑制和免疫调控作用。本文通过梳理芬戈莫德的研发流程,阐述结构优化和改造步骤,为药物化学研究提供经验。 |
| 关键词: 芬戈莫德 ISP-Ⅰ 多发性硬化症免疫调节剂 |
| DOI:10.13506/j.cnki.jpr.2015.12.001 |
| 基金项目:国家自然科学基金面上项目(No.81473110) |
|
|
|
| A research and development overview of Fingolimod |
| NIU Jun-xing,HU Li-hong |
| (Shanghai Research Center for Modernization of Traditional Chinese Medicine,Shanghai Institute of Materia Medica,Chinese Academy of Sciences) |
| Abstract: |
| Fingolimod (FTY720),a novel immunomodulator agent, is developed from ISP-1,which is a secondary metabolites of fungi.It was approved by FDA in 2012 for the treatment of autoimmune disease multiple sclerosis.Unlike the traditional immunosuppressive agents,fingolimod exerts immunosuppressive and immunoregulatory functions mainly through interaction with shhingosine-1-phosphate receptors (S1PR) on the cell surface without affecting activation and proliferation of lymphocyhtes.This article briefly reviewed the development process of fingolimod,elaborate the structural optimization and transformation,in order to provide experience for chemical rsearch. |
| Key words: Finglimod ISP-1 Multiple Sclerosis Immunomodulator |